STUART, Fla., Sept. 8, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc. (Stuart), a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, has announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,684,651, with granted claims for compositions of matter and methods of use in a variety of anterior segment indications in ophthalmology.
STUART, Fla., Jan. 9, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc. announces that it has expanded its drug development pipeline, adding programs in diabetic macular edema and myopia. The company has completed initial pre-clinical studies showing potential promise for Stuart's PolyColTM collagen mimetic peptide platform as a therapeutic approach for these indications. Pre-clinical studies show that PolyCol collagen mimetic peptides (CMPs) can reverse the damage to scleral collagen caused by excess matrix metalloproteinase that is a hallmark of myopia progression. In primate studies, CMPs administered via drop formulation were found to localize to the basement membranes of choroidal vasculature and in the central retinal artery. These results, combined with previously demonstrated CMP repair of membranes, suggests a new mechanism for treating diabetic macular edema. Both of these programs expand Stuart's development of CMPs, and join other programs in ocular surface disease, including dry eye, visual field loss associated with glaucoma and dry age-related macular degeneration.
STUART, Fla., Jan. 3, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc., (hereinafter Stuart) announces that it has entered into a license agreement with AJU Pharm Co. Ltd. (hereinafter AJU), for Stuart's clinical stage drug candidate ST-100. Under this agreement, AJU has the exclusive right to develop and commercialize ST-100 for South Korean and certain Southeast Asian markets in exchange for certain financial and other consideration to Stuart.
Stuart Therapeutics, Inc. (Stuart), a clinical stage company developing advanced ophthalmic therapeutics, announced today that the United States...
Stuart Therapeutics, Inc. (Stuart), a clinical stage company headquartered in Stuart, Florida that is developing advanced ophthalmic therapeutics,...
STUART, Fla., Jan. 3, 2022 /PRNewswire/ -- Stuart Therapeutics, Inc. (STUART), a clinical stage, innovative ophthalmic therapeutic development company, today announced the topline results of the first in human Phase 2 clinical trial for its lead drug candidate, ST-100 in patients with dry eye disease. The clinical trial, conducted between June and October 2021, was a multi-center, randomized, controlled, double masked clinical trial to evaluate the acute and chronic efficacy of topical ST-100 eyedrops on the signs and symptoms of dry eye disease. One hundred and sixty patients were enrolled, and received twice daily dosing of either 20mg/ml or 50mg/ml of ST-100, or placebo.